Lin et al.39 described that the Akt inhibitor MK-2206 enhances the efficacy of cisplatin and paclitaxel in vitro, in both Akt-active and Akt-inactive ovarian cancer cells, but through different mechanisms that include the inhibition of Akt signaling, induction of ROS, and restoration of p53 levels. This evidence concerns the gene AKT1 and ovarian cancer.